Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
Immunic Announces Closing of Oversubscribed Private Placement Financing
04:05pm, Tuesday, 17'th Feb 2026
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, I
Immunic closes $200M private placement to fund late-stage MS trials
11:33am, Tuesday, 17'th Feb 2026
Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential...
Immunic MS trial shows reduced brain lesions - ICYMI
08:26am, Saturday, 14'th Feb 2026
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company's phase 2
Immunic MS trial shows reduced brain lesions - ICYMI
03:03am, Saturday, 14'th Feb 2026
Immunic Inc (NASDAQ:IMUX)’s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego,...
Immunic Stock Jumps After Pricing $400 Million Private Placement
11:25am, Friday, 13'th Feb 2026
Immunic Inc (NASDAQ: IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
09:10am, Friday, 13'th Feb 2026
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition to
Leading bank calls AI threat to enterprise software "illogical," upgrades five stocks for 2026
08:30am, Friday, 13'th Feb 2026
Wall Street's panic over artificial intelligence replacing enterprise software is misguided, according to HSBC's latest research report. The investment bank...
– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, I
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
04:03am, Friday, 13'th Feb 2026
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the...
Wall Street 's mixed signals. Dow set for positive start as Nasdaq and S&P mark time
03:14am, Tuesday, 10'th Feb 2026
Ahead of the bell: Dow set to plough further into record territory US equity futures edged cautiously higher on Tuesday, keeping markets within touching...
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS
08:47am, Wednesday, 04'th Feb 2026
Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the ACTRIM
– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-C
Immunic targets MS market with Phase 3 data - ICYMI
12:27pm, Saturday, 10'th Jan 2026
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER s
Immunic targets MS market with Phase 3 data - ICYMI
07:01am, Saturday, 10'th Jan 2026
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s major milestones in 2025 and key expectations for 2026. He...
Immunic looks to 2026 data as late-stage MS program advances
09:17am, Wednesday, 07'th Jan 2026
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-te
